Is the new Novo Nordisk “improved” insulin worth a 60-70% price hike? The market says ‘no.’

Posted on Posted in Part D Precription Drug, Prescription Drug Plan

My clients regularly ask why brand name medications are so expensive. This great article by WSJ reporter Denise Roland helps explain the game. “In traditional marketing, a product line extension is the use of an established brand name for a new item with new flavors, forms, colors, added ingredients, package sizes.” Novo Nordisk repackaged its long lasting insulin with some tweaks and expected a 60-70% price increase over the previous product. Crazy, huh? The German (single payer) pricing board said as this product extension offers no real advantage in controlling diabetes there is no justification for a price difference. Other European national health plans acted in kind. However, once our FDA approves the product for safety it may be rolled out at the boosted price level which Medicare cannot negotiate. It’s the law.
Click this link to the Wall Street Link to WSJ Article 

Leave a Reply